Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Success! The link has been copied to your clipboard.
Stewardship is defined in Webster’s dictionary as the conducting, supervising, or managing of something—especially the careful and responsible management of something entrusted to one’s care. Stewardship is an important concept within the realm of medicine, and it is a concept with which all members of the renal care team are intimately familiar. The ESRD care team is entrusted with the care of a population of patients with a substantial disease burden. That disease burden leads to and often includes the development of infections.
According to the 2017 United States Renal Data System Annual Data Report, the adjusted all-cause hospitalization rate for the ESRD population has dropped from 2.03 in 2006 to 1.70 in 2015.1 Although hospitalizations due to cardiovascular disease have declined sharply over the past decade, the rate of infection-related hospitalizations remains relatively flat (Figure 1). Infection now accounts for approximately the same number of hospital admissions as cardiovascular disease.
FIGURE 1 | Cause-specific hospitalization rates
Antibiotic stewardship is a relatively new concept whose roots can be traced to the acute care setting. A recent consensus statement defined antibiotic stewardship as “coordinated interventions designed to improve and measure the appropriate use of antibiotic agents by promoting the selection of the optimal antibiotic drug regimen including dosing, duration of therapy, and route of administration.”2 One of the principal goals of an antibiotic stewardship program is to avoid the unintended consequences that may occur with antibiotic use.
In a recently published study of adverse events related to antibiotic use in hospitalized patients, the authors note that 20 percent of the patients exposed to at least 24 hours of oral or IV antibiotics experienced one or more adverse events.3 Antibiotic stewardship creates the opportunity to reduce the risk of:
While not entirely relevant for the outpatient dialysis setting, it is constructive to review approaches to antibiotic stewardship in the hospital setting. In 2016, the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy proposed 10 key points to consider when prescribing antibiotics within the inpatient setting.5 Those recommendations included:
Of course, the majority of antibiotic use today occurs in the outpatient setting. According to the Centers for Disease Control and Prevention (CDC), almost 270 million prescriptions for antibiotics were filled by US pharmacies in 2015, “enough for five out of every six people to receive one antibiotic prescription each year.”6 The CDC is quick to point out that at least 30 percent of those prescriptions were unnecessary.7 Within this context, recommendations have emerged regarding the establishment of outpatient antibiotic stewardship programs.8
Recent studies within the ESRD population highlight the opportunities that exist for antibiotic stewardship. FMCNA’s experience with Staphylococcus was published in a 2012 article and serves to highlight one such opportunity.9 Examining data from almost 300,000 patients, the authors reported a rate of bacteremia of 15.4 per 100 outpatient years. S. aureus accounted for 4 of the 15.1 episodes per 100 outpatient years. Surprisingly, among the patients empirically treated with vancomycin who were subsequently identified as patients with methicillin-sensitive S. aureus (MSSA), over 50 percent were still receiving vancomycin one week after the index culture was obtained (Figure 2). As noted in this study, cefazolin is the preferred choice for MSSA in patients without a contraindication. Despite this, at two weeks, twice as many patients with MSSA were still receiving vancomycin compared with cefazolin. Narrowing the antibiotic spectrum based on culture results is a key tenet of antibiotic stewardship, and it is widely believed that this practice attenuates the emergence of antimicrobial resistance.
More recently, FreseniusRx collaborated with the Fresenius End Stage Renal Disease Seamless Care Organizations (ESCOs) and explored the prospect of involving a clinical pharmacist when patients develop bacteremia. During the three-month program, all positive blood cultures and the antibiotics selected were reviewed by a pharmacist. In several instances, the pharmacist recommended changes to the existing antibiotic regimen. Significantly, the pharmacist’s recommendations were universally accepted by the local care team. Many of the recommendations made by the pharmacists in this program were related to narrowing the antibiotic spectrum.
FIGURE 2 | Prevalence of vancomycin and cefazolin in ESRD patients with MSSA bloodstream infection
As noted above, much has been written about the establishment of outpatient antibiotic stewardship programs. In late 2016, the CDC published a paper entitled “Core Elements of Outpatient Antibiotic Stewardship.”10 The authors specifically described four core elements of a successful program:
Building on our experience and leadership in this field, FMCNA has established a formal antibiotic stewardship program. With each of the four core elements in mind, the FMCNA Antibiotic Stewardship program will serve both hemodialysis and peritoneal dialysis (PD) patients. Bacteremia will be the initial focus, with special attention directed to clinics experiencing high rates of bloodstream infections (BSI). Ultimately the program will include PD-associated peritonitis, as well as other infections requiring antimicrobial therapy. The program will support antibiotic selection, dose, duration, and route of administration. Antibiograms will be actively monitored, both to inform empiric therapy and monitor the emergence of resistance. As the program expands, antibiotic utilization and empiric choices will be reviewed, and recommendations will be made to standardize the approach where clinically warranted
Reporting bloodstream infections is a 2018 national quality measure for outpatient dialysis facilities. Reducing bloodstream infections is a laudable goal, and it is one Fresenius Kidney Care is pursuing in many ways, including by participating in the CDC’s Dialysis BSI Prevention Collaborative.11 But when serious infections occur, adding a clinical pharmacist to the care team will prove invaluable to our patients. In summary, working collaboratively with the local care team, the Fresenius Antibiotic Stewardship program will optimize the care for patients who require antibiotics and minimize the risk of unintended consequences that can accompany antibiotic utilization.
Terry Ketchersid, MD, MBA
Senior Vice President, Chief Medical Officer, Integrated Care Group, Fresenius Medical Care
Terry Ketchersid has clinical oversight over FMCNA’s Integrated Care Group, which includes value-based care and pharmacy initiatives. He received his bachelor’s degree in chemistry from Austin College, his executive master of business administration from Duke University’s Fuqua School of Business, and his doctor of medicine degree from the University of Texas Southwestern Medical School.
by Terry Ketchersid, MD, MBA